How is risk status used to determine the duration of adjuvant therapy for colon cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

For patients with stage III colon cancer, National Comprehensive Cancer Network (NCCN) guidelines recommend basing adjuvant treatment duration on risk status, as follows [92] :

  • Low-risk stage III: CapeOx for 3 mo or FOLFOX for 3-6 mo
  • High risk stage III: CapeOx for 3-6 mo or FOLFOX for 6 mo

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!